Stem Cell Therapy for Chronic Kidney Disease

Recruiting in Palo Alto (17 mi)

+1 other location

Overseen byLaTonya Hickson, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: LaTonya J. Hickson

No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial is testing if using donor stem cells is safe and tolerable for people with chronic kidney disease. The stem cells might help repair their damaged kidneys. Stem cell therapy has shown potential in treating kidney diseases and aiding in kidney regeneration.

Research Team

LaTonya Hickson, MD

Principal Investigator

Mayo Clinic

Eligibility Criteria

This trial is for adults aged 30-80 with chronic kidney disease, specifically those not on dialysis or with a transplant history. Participants must have certain levels of kidney function and protein in their urine, and can't be pregnant, heavy smokers, drug users, or have uncontrolled diseases like severe anemia.

Inclusion Criteria

Ability to give informed consent

I am between 30 and 80 years old.

Your kidney function, as measured by eGFR, is between 25 and 55 ml/min/1.73m^2.

See 1 more

Exclusion Criteria

I am unable to understand and give consent for treatment.

I currently have an infection.

I have liver cirrhosis.

See 24 more

Treatment Details

Interventions

Allogeneic adipose-derived mesenchymal stem cells (MSC)-Single Infusion (Mesenchymal Stem Cell Therapy)
Allogeneic adipose-derived mesenchymal stem cells (MSC)-Two Infusions (Mesenchymal Stem Cell Therapy)

Trial OverviewThe study tests the safety of using stem cells from fat tissue to treat chronic kidney disease. Patients will receive either one or two infusions of these cells to see how well they tolerate them and any potential benefits.

Participant Groups

2Treatment groups

Experimental Treatment

Group I: Dose Arm 2Experimental Treatment1 Intervention

Subjects with chronic kidney disease will receive a single intravenous infusion of allogeneic adipose tissue-derived mesenchymal stem cells (MSC) of 150x10\^6 cells at day 0.

Group II: Dose Arm 1Experimental Treatment1 Intervention

Subjects with chronic kidney disease will receive allogeneic adipose tissue-derived mesenchymal stem cells (MSC) in two intravenous infusions of 75x10\^6 cells at day 0 and month 3.